Janssen Cilag Prostate Cancer Approved for NHS Use

As reported by the BBC, Janssen Cilag’s drug for advanced prostate cancer has been approved for use by the National Health Service (NHS).

Janssen Cilag is one of the world’s leading research-based pharmaceutical companies, and the prostate cancer drug that they manufacture, Abirateron has been shown to extend the lives of late-stage prostate cancer sufferers by more than three months.

The National Institute for Health and Clinical Excellence (NICE) have revised their recommendations and prostate cancer drug is now approved for used by the National Health Service. Janssen will be providing the prostate cancer drug to the NHS at a discounted price.

Janssen Cilag Prostate Cancer Approved for NHS Use

Developed by the Institute of Cancer Research, the prostate cancer drug took two decades to develop, as Professor Alan Ashworth explains, “This drug was discovered at the Institute of Cancer Research and is the result of more than two decades of dedicated work by our scientists and collaborators.

“In clinical trials of men with advanced prostate cancer who have already tried chemotherapy, it has been shown to extend life by an average of four months and improve quality of life.”

Are you looking for a new oncology job in the pharmaceutical industry?

Click here to search our current oncology jobs now.

Posted in: Featured Jobs, News
CK Logo in place of featured image